Recent advances in acute lymphoblastic leukemia

Oncology

Volumn 25, Issue 4, 2011, Pages

  Pui, Ching Hon ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEXAMETHASONE; FOLINIC ACID; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE; JANUS KINASE INHIBITOR; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; PROTEIN CRLF2; PROTEIN IKZF1; TRANSCRIPTION FACTOR ERG; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RESEARCH; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL EFFECTIVENESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; PATIENT COMPLIANCE; PHARMACOGENETICS; PROGNOSIS;

EID: 79956220271     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Eng J Med. 2004;350:1535-48.
3. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470-80.
4. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitorand Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41:1243-6.
5. Mullighan, CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009;106:9414-8.
6. Mullighan CG, Su X, Phillips LAA, et al. ERG deletion defines a novel subtype of acute lymphoblastic leukemia. Nat Genet. In press 2011.
7. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235-9.
8. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;9:551-65.
9. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011;89:387-91.
10. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293:1485-9.
11. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6 mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood. 2009;113:6077-84.
12. Stanulla M, Schaeffeler E, Möricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols. Blood. 2009;114:1314-18.
13. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet. 2008;371:1030-43.
14. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730-41.
15. Pui CH, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011;29:386-91.
16. Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genet. 2011;43:237-41.
17. Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265-84.
18. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11:1096-1106.
19. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol. 2009;10:957-66.